Jacob Gottlieb is the owner and portfolio manager of a New York hedge fund firm, Altium. He focuses on investing in firms in the healthcare industry as he is very experienced in this area and holds a medical degree himself. He is sharing office space with an old colleague of his, Stuart Weisbrod. They had worked closely together in the past at Merlin BioMed Group which was also a hedge fund management firm.
Stuart Weisbrod was one of the co-founders of Merlin BioMed. Jacob Gottlieb first started working at his firm in 2000. While he was working for Merlin BioMed it had fantastic returns, earning a return of 100 percent in 2000, for instance. These fantastic returns resulted in their picking up a number of very prominent clients including endowments, pension funds, and high net worth individuals. While this firm had been successful for a number of years they wound down operations in 2007.
Stuart Weisbrod now owns and operates Iguana Healthcare Partners. Like Jacob Gottlieb’s Altium he focuses on biotech firms, pharmaceuticals, healthcare services, healthcare information tech firms, and medical devices. They share ideas about what companies to invest in and what financial strategies to take.
Jacob Gottlieb had owned another hedge fund firm, Visium Asset Management, for a number of years. He started out with $300 million in seed money and grew it into a fund worth $2.5 billion. He had 200 people working for him and offices in New York City, San Francisco, and London. This company came to a sudden end, though, in 2016.
Jacob Gottlieb said that unbeknownst three of his executives had been doing insider trading deals and mismarking. This was uncovered by a whistleblower, Jason Thorell, who collected evidence of their schemes for the SEC and FBI.
He was personally absolved of any wrongdoing but he did have to wind down the business of Visium Asset Management and sell its investments over the course of the next year. He has put all that behind him, though, and Jacob Gottlieb is poised for future success at Altium.